Astec LifeSciences Limited — Others, 23-04-2025: Disclosure under Regulation 52(4)

The company has announced a board meeting to discuss the financial results for the quarter and half-year. This update is likely to provide insights into the company's performance, with anticipated implications for operational efficiency and financial health. Monitoring these results will be key for shareholders, as they may indicate growth trends or operational challenges. Overall, this disclosure sets the stage for an informed analysis of the company’s trajectory and may influence investor sentiment, with a potential positive outlook depending on the results shared.